Source: International Congress 2019 – Pulmonary hypertension with lung diseases and experimental pulmonary hypertension
Disease area: Interstitial lung diseases, Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
I. Roger (Valencia, Spain), C. Estornut (Valencia, Spain), B. Ballester (Valencia, Spain), J. Milara (Valencia, Spain), J. Cortijo (Valencia, Spain). Role of IL-11 in vascular function of pulmonary fibrosis patients. 1424

Member's Comments

No comment yet.

Related content which might interest you: Role of JAK2/STAT3 pathway in vascular function of pulmonary fibrosis patients Source: International Congress 2015 – Pulmonary hypertension: promising small molecules Year: 2015 PP309 – Effect of elexacaftor-tezacaftor-ivacaftor on pulmonary and endothelial function in a patient with advanced cystic fibrosis Source: ERS Lung Science Conference 2021 Year: 2021 The role of chemokines and cytokines in lung fibrosis Source: Eur Respir Rev 2008; 17: 151-156 Year: 2008 Role of TGF-beta and IFN-gamma in interstitial pulmonary fibrosis Source: Eur Respir J 2004; 24: Suppl. 48, 719s Year: 2004 Role of interleukin-10 in idiopathic pulmonary fibrosis Source: Eur Respir J 2004; 23: 179-180 Year: 2004 Increased fibrinolytic mediators in IPF as potential contributors to pulmonary fibrosis and vascular remodeling Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 VEGF gene transfer enhances fibrosis but improves pulmonary hemodynamics in experimental pulmonary fibrosis Source: Annual Congress 2008 - Animal models of pulmonary fibrosis: mechanisms and therapies Year: 2008 VEGF expression does not differentiate between idiopathic pulmonary fibrosis and pulmonary sarcoidosis Source: Eur Respir J 2007; 30: Suppl. 51, 574s Year: 2007 VEGF reduces pulmonary hypertension and vascular remodeling in pulmonary fibrosis through reduced endothelial apoptosis Source: Annual Congress 2009 - Pulmonary circulation I Year: 2009 Angiogenic activity of sera from patients with various types of pulmonary fibrosis in relation to pulmonary functions Source: Annual Congress 2009 - Pathological remodelling in chronic lung disease: from epithelial-mesenchymal transition to cellular activation Year: 2009 Sildenafil inhibit dose-dependently profibrotic and remodelling effects of TGFbeta1 on pulmonary arteries from patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Expression of macrophage migration inhibitory factor in patients with idiopathic pulmonary fibrosis Source: International Congress 2015 – Interstitial lung diseases II Year: 2015 Decreased BCL-2 expression in alveolar macrophages of patients with idiopathic pulmonary fibrosis Source: Annual Congress 2010 - Biomarkers in diffuse parenchymal lung disease Year: 2010 Effect of pirfenidone on TGF-beta-induced pro-fibrotic effects in primary human lung cells derived from patients with idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 2 Year: 2014 Role of MUC4 in idiopathic pulmonary fibrosis Source: International Congress 2019 – Translational aspects of idiopathic pulmonary fibrosis Year: 2019 Role of MUC4 in idiopathic pulmonary fibrosis Source: International Congress 2018 – Back to basics and translational research in idiopathic interstitial pneumonias Year: 2018 Tranilast inhibits pulmonary fibrosis by suppressing TGFbeta-mediated extracellular matrix protein production Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 Increased polysialylation in lung tissue of patients with idiopathic pulmonary fibrosis Source: Annual Congress 2011 - Cell biology of lung disease Year: 2011 Potential contribution of precursor cells to vascular remodeling in the AdTGF-β1 model of lung fibrosis and pulmonary hypertension Source: Annual Congress 2011 - Experimental pulmonary hypertension Year: 2011 Association between diffusion capacity and endothelial function in patients with idiopathic pulmonary fibrosis Source: International Congress 2018 – Sarcoidosis, interstitial lung diseases and various clinical problems Year: 2018